

Program at a glance

DATE / VENUE		Room 1 (Park Ballroom 1, 5F)	Room 2 (Park Ballroom 2, 5F)	Room 3 (Park Ballroom 3, 5F)	Room 4 (Studio 1+2+3, 6F)	Room 5 (Studio 4, 6F)
Day 1. Sep. 2(Thu) 2021		Pre-Congress Symposium				
	15:30-17:00	National Obesity Strategy in The Era of COVID-19				
	18:30-19:00	Break Time				
	19:00-20:00	Satellite Symposium 1 (Daiichi-Sankyo)	Satellite Symposium 2 (Boehringer Ingelheim)			
		Prevention of CVD in Hypertension with Diabetes Mellitus	How to Approach Patients with Type 2 Diabetes in Perspective of Cardio-Renal Metabolism and Current Treatment Algorithm			

Day 2. Sep. 3(Fri) 2021	07:30-08:00	Breakfast Symposium 1 (LG Chem)	Breakfast Symposium 2 (SANOFI)			
		The Renoprotective of Effect and Safety of Gemigliptin for Type 2 Diabetes	The Korean Titration Study: Simple & Easy Titration Method for Glargine 300			
	08:15-08:55	Keynote Lecture 1				
		Efficacy and Safety of Semaglutide in Japanese and Korean: STEP6 Study Takashi Kadowaki (The University of Tokyo Hospital, Japan)				
	08:55-09:00	Break Time				
	09:00~10:30	Symposium 1	Symposium 2	Symposium 3	Symposium 4	Sponsored Session 1 (MSD)
		Obesity and Cardiovascular Disease	Gut Microbiome, Obesity and Metabolic Disorders	Novel Mechanistic Insights of Appetite and Weight Control	Socioeconomic Inequalities in Obesity Epidemiology	
	10:30-10:40	Break Time				
	10:40-10:45	Opening Address				
		Jae Heon Kang (President of Korean Society for the Study of Obesity, Korea)				
	10:45-11:25	Plenary Lecture 1				
		Implication of Obesity in Cardiometabolic Risk Robert H. Eckel (University of Colorado Anschutz Medical Center, USA)				
	11:25-11:30	Break Time				
	11:30-12:30				Oral Presentation 1	Oral Presentation 2
	12:30-12:40	Break Time				
	12:40-13:40	Luncheon Symposium 1 (Alvogen)	Luncheon Symposium 2 (MSD)	Luncheon Symposium 3 (DAEWOONG)	Luncheon Symposium 4 (Chong Kun Dang Pharm)	
		Long-Term Efficacy & Safety on Combination Phentermine Plus Topiramate ER : Where Do We Stand?	Individualized T2DM Treatment Focus on Recent Treatment Option	Glycemic Control for Reversing Diabetes	Long-Term Efficacy & Safety on Combination Phentermine Plus Topiramate ER : Where Do We Stand?	
	13:40-15:10	Symposium 5	Symposium 6	Symposium 7	Symposium 8	Sponsored Session 2 (Alvogen)
		Obesity Drug	New Paradigm for Clinical Nutrition on Obesity (Untact)	COVID 19 and Obesity	Bariatric Surgery	Is Obesity a Comorbid Disease?
	15:10-15:30	Break Time				
	15:30-16:10	keynote Lecture 2				
		Role of GLP1 Analogues and Other Gut Hormones in Obesity Management John Wilding(University of Liverpool, UK)				
	16:10-17:40	Symposium 9	Symposium 10	Symposium 11	Symposium 12	Sponsored Session 3 (Novo Nordisk)
		Novel Insights into Obesity Comorbidities I	Elderly Obesity -Sarcopenic Obesity	COVID-19 and Impact on Childhood Obesity and Comorbidities	Enlightening the Future of Obesity through Publication	

Day 3. Sep. 4(Sat) 2021	07:30-08:00	Breakfast Symposium 3 (DALIM BIOTECH)	Breakfast Symposium 4 (Kwangdong)	Breakfast Symposium 5 (AJU PHARM)		
				What Do Physicians Consider to Treat ASCVD High-Risk Patient with Dyslipidemia?		
	08:15-08:55	Keynote Lecture 3				
		Precision Lifestyle Medicine to Manage Cardiometabolic Risk in Obesity Jean-Pierre Després (Laval University, Canada)				
	08:55-09:00	Break Time				
	09:00-10:30	Symposium 13	Symposium 14	Symposium 15	Symposium 16	Sponsored Session 4 (YUHAN)
		Novel insights into Obesity Comorbidities II	Circadian Influences (Rhythm) of Diet on Weight Control	Cutting Edge Basic Research and Methodology in Obesity Biology	New Approaches to Obesity Based on Psychiatric Views	Empagliflozin from RCT to Real World_How to Interpret
	10:30-10:40	Break Time				
	10:40-12:10	Symposium 17	Symposium 18	Symposium 19	Symposium 20	Sponsored Session 5 (Hanmi)
		Digital Therapeutics	The Effect of Exercise on Obesity and Related Metabolic Dysfunction	Cutting-edge in Pediatric Type 2 Diabetes	Obesity-Related Health Outcomes: A Lifecycle Perspective	Optimal Treatment Strategy for Dyslipidemia
	12:10-12:20	Break Time				
	12:20-13:20	Luncheon Symposium 5 (Handok)	Luncheon Symposium 6 (DONG-A ST)	Luncheon Symposium 7 (AstraZeneca)	Luncheon Symposium 8 (HK inno.N Corp.)	
		Exploring the Extended Benefits of Ipragliflozin Focusing on NAFLD	CV Safety of Evogliptin	Connecting the Dots from Diabetes to Heart Failure & Chronic Kidney Disease with Dapagliflozin	New Paradigm of Glycemic Variability EVERGREEN Study _Meta-Analysis	
	13:20-14:20				Oral Presentation 3	Oral Presentation 4
	14:20-14:30	Break Time				
	14:30-15:30	Best Article in JOMES	Hot Topic in Obesity 2021(1)	Hot Topic in Obesity 2021(2)	Cooking Class for Healthy Diet	Sponsored Session 6 (CELLTRION)
	15:30-15:40	Break Time				
	15:40-16:20	Keynote Lecture 4				
		System Biology and Metabolic Diseases Adil Mardinoglu (King's College London, UK / KTH-Royal Institute of Technology, Sweden)				
	16:20-16:30	Break Time				
	16:30-17:10	Plenary Lecture 2				
		Incretin-Based Obesity Treatment Michael A. Nauck(Ruhr-University, Germany)				
17:10-17:30	Closing & Award Ceremony					